Showing 1251-1260 of 21420 results for "".
- Lantheus Lists Two ASCO 2026 Oncology Imaging Presentationshttps://reachmd.com/news/lantheus-lists-two-asco-2026-oncology-imaging-presentations/2487137/Key Takeaways Lantheus announced two ASCO 2026 oncology imaging presentations covering osteosarcoma and early-stage prostate cancer. One item is a Monday, June 1 poster in the Sarcoma session, poster 376b, tied to a phase 1/2 LNTH-2403 study in relapse
- Dietary Nutrient Intake And Nutritional Status In Women With Infertilityhttps://reachmd.com/news/dietary-nutrient-intake-and-nutritional-status-in-women-with-infertility/2487135/Key Takeaways Higher riboflavin and calcium intake were associated with higher muscle mass percentage after adjustment. Vitamin E intake was inversely associated with hip circumference and prolactin after adjustment. No other nutrient-hormone
- SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lineshttps://reachmd.com/news/scale-2026-ipsen-reports-phase-2-corabotase-data-in-glabellar-lines/2487141/Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee. The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng ac
- Early Postoperative Intake Linked To Complications After GI Cancer Surgeryhttps://reachmd.com/news/early-postoperative-intake-linked-to-complications-after-gi-cancer-surgery/2487124/Key Takeaways Early postoperative energy intake showed a nonlinear association with overall complications from surgery for GI cancer. Infectious complications followed broadly similar directional patterns, and exploratory subgroup analyses of the energ
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://reachmd.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Colonoscopy Screening Lowers Incidence But Not Mortality After 13 Yearshttps://reachmd.com/news/colonoscopy-screening-lowers-incidence-but-not-mortality-after-13-years/2487091/Key Takeaways Invitation to colonoscopy was associated with lower colorectal cancer incidence at 13 years in this randomized population-based comparison. Incidence estimates were stronger in per-protocol analysis and appeared more pronounced for distal
- SYNCHRONIZE-1 Phase III Readout on Survodutidehttps://reachmd.com/news/synchronize-1-phase-iii-readout-on-survodutide/2487079/Key Takeaways Boehringer Ingelheim said survodutide met both co-primary endpoints in SYNCHRONIZE-1 under the efficacy and treatment-regimen estimands. A key secondary endpoint showed a statistically significant reduction in waist circumference versus p
- Stage IV Breast Cancer Incidence and Survival, 2010-2021https://reachmd.com/news/stage-iv-breast-cancer-incidence-and-survival-2010-2021/2487083/Key Takeaways The share of invasive breast cancers diagnosed as stage IV increased modestly from 5.6% in 2010 to 6.0% in 2021. Incidence increases were observed across subtype and demographic strata, although the magnitude varied between groups. <
- Orforglipron Maintains Weight Loss After Injectable Therapyhttps://reachmd.com/news/orforglipron-maintains-weight-loss-after-injectable-therapy/2487090/Key Takeaways Greater maintenance of prior weight loss was observed with once-daily oral orforglipron than placebo in both prior-injectable cohorts. All key secondary endpoints were met, including maintenance of at least 80% of the earlier weight reduc
- SCALE 2026: Ipsen to Present Phase II Corabotase Datahttps://reachmd.com/news/scale-2026-ipsen-to-present-phase-ii-corabotase-data/2487087/Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule. Corabotase is described by Ipsen as a custom-designed recombinant neuroi